P16ink4a Flow Cytometry of Exfoliated Cervical Cells: Its Role in Quantitative Pathology and Clinical Diagnosis of Squamous Intraepithelial Lesions.
Yifeng He,Jun Shi,Hui Zhao,Yuefei Wang,Chi Zhang,Sai Han,Qizhi He,Xiaolan Li,Shangji Li,Wenjing Wang,Muhua Yi,Xiaoling Hu,Zhihua Xing,Hao Han,Yinshuang Gao,Qing Zhou,Linlin Lu,Jianfen Guo,Hui Cao,Caiping Lu,Yanqiang Hou,Dan Chen,Fengyun Yang,Ping Lei,Wen Di,Ji Qian,Yi Xia,Youzhong Zhang,Yang Deng,Jianlong Zhu,Congjian Xu
DOI: https://doi.org/10.1002/ctm2.1209
IF: 8.554
2023-01-01
Clinical and Translational Medicine
Abstract:AbstractBackgroundP16INK4A is a surrogate signature compensating for the specificity and/or sensitivity deficiencies of the human papillomavirus (HPV) DNA and Papanicolaou smear (Pap) co‐test for detecting high‐grade cervical squamous intraepithelial lesions or worse (HSIL+). However, traditional p16INK4A immunostaining is labour intensive and skill demanding, and subjective biases cannot be avoided. Herein, we created a high‐throughput, quantitative diagnostic device, p16INK4A flow cytometry (FCM) and assessed its performances in cervical cancer screening and prevention.MethodsP16INK4A FCM was built upon a novel antibody clone and a series of positive and negative (p16INK4A‐knockout) standards. Since 2018, 24 100‐women (HPV‐positive/‐negative, Pap‐normal/‐abnormal) have been enrolled nationwide for two‐tier validation work. In cross‐sectional studies, age‐ and viral genotype‐dependent expression of p16INK4A was investigated, and optimal diagnostic parameter cut‐offs (using colposcopy and biopsy as a gold standard) were obtained. In cohort studies, the 2‐year prognostic values of p16INK4A were investigated with other risk factors by multivariate regression analyses in three cervicopathological conditions: HPV‐positive Pap‐normal, Pap‐abnormal biopsy‐negative and biopsy‐confirmed LSIL.ResultsP16INK4A FCM detected a minimal ratio of 0.01% positive cells. The p16INK4A‐positive ratio was 13.9 ± 1.8% among HPV‐negative NILM women and peaked at the ages of 40–49 years; after HPV infection, the ratio increased to 15.1 ± 1.6%, varying with the carcinogenesis of the viral genotype. Further increments were found in women with neoplastic lesions (HPV‐negative: 17.7 ± 5.0–21.4 ± 7.2%; HPV‐positive: 18.0 ± 5.2–20.0 ± 9.9%). Extremely low expression of p16INK4A was observed in women with HSILs. As the HPV‐combined double‐cut‐off‐ratio criterion was adopted, a Youden's index of 0.78 was obtained, which was significantly higher than that (0.72) of the HPV and Pap co‐test. The p16INK4A‐abnormal situation was an independent HSIL+ risk factor for 2‐year outcomes in all three cervicopathological conditions investigated (hazard ratios: 4.3–7.2).ConclusionsFCM‐based p16INK4A quantification offers a better choice for conveniently and precisely monitoring the occurrence of HSIL+ and directing risk‐stratification‐based interventions.